跳至主要内容
临床试验/NCT03843671
NCT03843671尚未招募2 期

A Phase II Randomized Sham-Controlled Trial With Allocation Concealment and Blinded Patients and Assessors, Investigating Hyperbaric Oxygen as a Radiation Sensitizer for Locally Advanced Squamous Cell Carcinoma of the Oropharynx and Larynx

National Baromedical Services5 个研究点 分布在 2 个国家目标入组 400 人开始时间: 2019年7月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
尚未招募
发起方
入组人数
400
试验地点
5
主要终点
Progression free survival

研究概览

简要总结

There is reason to believe that hyperbaric oxygen administered immediately prior to radiotherapy will prove beneficial for this cancer type and stage. The basis for this hypothesis is a review of several decades of published work, the conclusion of a recent (2018) Cochrane Review, and results of a Phase I trial.

详细描述

The goal of this research is to address the question:

"Does the addition of hyperbaric oxygen to radiation and chemotherapy improve outcomes in locally advanced oropharyngeal or laryngeal squamous cell carcinoma?"

There is reason to believe that hyperbaric oxygen administered immediately prior to radiotherapy will prove beneficial for this cancer type and stage. The basis for this hypothesis is a review of several decades of published work, the conclusion of a recent (2018) Cochrane Review, and results of a Phase I trial. A summary of this body of work follows.

During the 1950's, several reports laid the groundwork for hyperbaric oxygen's potential as an effective radiation sensitizer. Gray and colleagues observed that curability of small animal tumors with radiotherapy was limited by the radio-resistance of the portion of cells that retain their reproductive integrity.(1) Tumor cell sensitivity to irradiation was seen to increase when tumor-bearing mice breathed oxygen under hyperbaric conditions. Gray's group further observed that radiobiological damage demonstrates dependence on the concentration of oxygen in the immediate vicinity of tumor cells at the time of radiation.( 2) It became evident that many solid tumor cell populations exist within a wide range of oxygen tensions.(3) These findings were sufficiently encouraging to warrant a small clinical study to determine if this anticipated radio-sensitization effect could be demonstrated histologically.(4) A small diver recompression chamber was acquired from the Royal Navy and modified to accommodate a recessed acrylic window.(5)

The trial involved eight patients whose breast or lung tumor sites would lie directly below the window, above which a radiation delivery source was mounted. To assess any difference afforded by hyperbaric oxygen, tumors had to be large enough so they could addressed in two aspects. Irradiation of the inferior aspect occurred conventionally, with the superior aspect shielded. Shielding was then reversed and the superior aspect irradiated while patients breathed oxygen to 3.0 atmospheres absolute.(4) Preliminary findings of increased tumor destruction secondary to hyperbaric oxygen exposure promoted investigators to treat another 35 patients in this manner. Despite their uniformly poor prognosis, the hyperbaric effect was again significant and outcomes were deemed "much better than anticipated".(6)

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Outcomes Assessor)

盲法说明

Both groups compressed in a hyperbaric chamber. Patients will be unaware of the compression gas or degree of pressurization as references to each are obscured

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with histological or microscopic proof (from the primary tumor and/or lymph nodes) of invasive squamous cell carcinoma of the oral cavity, oropharynx or larynx (World Health Organization type 1).
  • Stage III or IV disease, M0
  • Non-surgical candidate; for reasons of health or age (except biopsy)
  • Human Papillomavirus (P16) negative
  • Life expectancy of at least 6 months and a Karnofsky performance status of ≥ 70
  • Age ≥ 18 years
  • No distant metastatic disease
  • No clinically significant heart disease:
  • No significant ventricular arrhythmia requiring medication with antiarrhythmic. No symptomatic coronary artery disease (angina). No myocardial infarction within the last 6 months. No second or third degree heart block or bundle branch block or clinically significant conduction system abnormality.
  • Patients must sign a study-specific informed consent form

排除标准

  • Histology other than squamous cell carcinoma
  • Evidence of metastasis (below the clavicle or distant) by clinical or radiographic means
  • History of prior invasive malignancy, unless at least 5 years without evidence of recurrence (tumor-specific restaging)
  • Prior resection of the primary tumor or lymph node, unless un-operated N2-N3 nodal disease or primary tumor remaining, respectively.
  • Prior chemotherapy for head and neck cancer or radiotherapy to the head and neck
  • Prior treatment with Bleomycin
  • Creatinine clearance: measured or estimated Glomerular Filtration Rate <40 ml/min.
  • Patients with simultaneous primaries
  • Participating in a conflicting protocol
  • Pulmonary pathologies (risk of decompression-induced pulmonary barotrauma)
  • Current, untreated pneumothorax. Previous history of spontaneous pneumothorax. Previous history of intrathoracic surgery. History or evidence of pulmonary blebs or bullous lung disease. Clinically significant chronic obstructive pulmonary disease, associated with carbon dioxide retention, poorly controlled or associated with acute bronchospasm.
  • Where the hyperbaric physician deems the patient to have an otherwise unacceptable risk for hyperbaric chamber exposure
  • Claustrophobia

研究组 & 干预措施

Group 1

Experimental

Hyperbaric oxygen Hyperbaric chamber

干预措施: Hyperbaric oxygen (Drug)

Group 1

Experimental

Hyperbaric oxygen Hyperbaric chamber

干预措施: Hyperbaric chamber (Device)

Group 2

Sham Comparator

Sham for hyperbaric oxygen Hyperbaric chamber

干预措施: Hyperbaric oxygen (Drug)

Group 2

Sham Comparator

Sham for hyperbaric oxygen Hyperbaric chamber

干预措施: Hyperbaric chamber (Device)

结局指标

主要结局

Progression free survival

时间窗: Two years

Per blinded radiotherapy assessor

Relapse free survival

时间窗: Two years

Per blinded radiotherapy assessor

次要结局

  • Overall survival(Two years)
  • Incidence and degree of acute radiation toxicity(At seven weeks from start of protocol, having completed 35 radiotherapy treatments)
  • Incidence and degree of late radiation tissue injury(Two years)
  • Hyperbaric protocol and radiotherapy dosing protocol compliance(Approximately 45 days after initiation of protocol)
  • Subject quality of life: Rating scale(Two week post RT, then 3, 6, 12 & 24 months post radiotherapy)
  • Incidence of acute hyperbaric complications; ear/sinus barotrauma, oxygen toxicity, myopia, confinement anxiety(At seven weeks from start of protocol, having completed 35 hyperbaric chamber exposures)

研究者

发起方
National Baromedical Services
申办方类型
Other
责任方
Sponsor

研究点 (5)

Loading locations...

相似试验